AnaptysBio Spin-Off Yields $140M Cash and >95% EBIT Margin
AnaptysBio completed the spin-off of First Tracks Biotherapeutics, distributing one TRAX share for each AnaptysBio share and launching with $140–145 million in net cash. It will exclusively manage Jemperli royalties with GSK and imsidolimab royalties with Vanda under a virtual model targeting over 95% EBIT margin.
1. Spin-Off Details
AnaptysBio completed the taxable spin-off of First Tracks Biotherapeutics and distributed one share of First Tracks common stock (TRAX) for each AnaptysBio share held as of the April 6, 2026 record date. Both companies now trade separately under ANAB and TRAX symbols.
2. Financial Position
The company launched with a virtual business model and net cash of approximately $140–145 million, positioning it for robust liquidity and shareholder returns.
3. Royalty Management Strategy
AnaptysBio will exclusively manage financial collaborations for Jemperli with GSK and imsidolimab with Vanda, prioritizing protection and return of royalty value to shareholders.
4. Operational Efficiency
With limited full-time employees and minimal operating expenses, AnaptysBio targets an operating margin exceeding 95%, reflecting its streamlined royalty management structure.